img

Global Oncolytic Virus Cancer Immunotherapy Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Oncolytic Virus Cancer Immunotherapy Market Research Report 2024

Oncolytic virus is a special virus that can beneficially infect and kill cancer cells. These are deployed as part of cancer immunotherapy and work by selectively targeting cancer cells and performing oncolytics. Oncolytic viruses can not only kill cancer cells directly, but also stimulate patients' own anti-tumor immune response.
According to MRAResearch’s new survey, global Oncolytic Virus Cancer Immunotherapy market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oncolytic Virus Cancer Immunotherapy market research.
The first oncolytic virus immunotherapy was approved in Latvia in 2004 for the treatment of cutaneous melanoma. Inevitable changes in the environment due to human activities are causing various factors, leading to an increase in the incidence of many skin malignancies, including non-melanoma skin cancer. Conventional radiation and chemotherapy known to treat various cancers, including cutaneous melanoma, have a limited therapeutic index and a range of treatment-related side effects.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Oncolytic Virus Cancer Immunotherapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
Segment by Type
Monoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines

Segment by Application


Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Oncolytic Virus Cancer Immunotherapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Monoclonal Antibodies
1.2.3 Checkpoint Inhibitors
1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines
1.3 Market by Application
1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Head and neck Cancer
1.3.8 Ovarian Cancer
1.3.9 Pancreatic Cancer
1.3.10 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2018-2033)
2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Region
2.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Size by Region (2018-2023)
2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2024-2033)
2.3 Oncolytic Virus Cancer Immunotherapy Market Dynamics
2.3.1 Oncolytic Virus Cancer Immunotherapy Industry Trends
2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers
2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges
2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue
3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2018-2023)
3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2018-2023)
3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue
3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio
3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2022
3.5 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served
3.6 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
3.7 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type
4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2018-2023)
4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2024-2033)
5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application
5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2018-2023)
5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2018-2033)
6.2 North America Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2018-2033)
7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size (2018-2033)
8.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2018-2033)
9.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
9.4 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size (2018-2033)
10.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction
11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.1.5 AstraZeneca Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction
11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.2.5 Amgen Recent Development
11.3 F Hoffman-La Roche
11.3.1 F Hoffman-La Roche Company Detail
11.3.2 F Hoffman-La Roche Business Overview
11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction
11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.3.5 F Hoffman-La Roche Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction
11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.5.5 Novartis AG Recent Development
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Detail
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction
11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.6.5 Merck & Co., Inc. Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction
11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Biovex
11.8.1 Biovex Company Detail
11.8.2 Biovex Business Overview
11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction
11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.8.5 Biovex Recent Development
11.9 Cell Genesys
11.9.1 Cell Genesys Company Detail
11.9.2 Cell Genesys Business Overview
11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction
11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.9.5 Cell Genesys Recent Development
11.10 Crusade Laboratories
11.10.1 Crusade Laboratories Company Detail
11.10.2 Crusade Laboratories Business Overview
11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction
11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.10.5 Crusade Laboratories Recent Development
11.11 Genelux Corporation
11.11.1 Genelux Corporation Company Detail
11.11.2 Genelux Corporation Business Overview
11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction
11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.11.5 Genelux Corporation Recent Development
11.12 Lokon Pharma
11.12.1 Lokon Pharma Company Detail
11.12.2 Lokon Pharma Business Overview
11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction
11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.12.5 Lokon Pharma Recent Development
11.13 MultiVir
11.13.1 MultiVir Company Detail
11.13.2 MultiVir Business Overview
11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction
11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.13.5 MultiVir Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Checkpoint Inhibitors
Table 4. Key Players of Oncoloytic Viral Therapies and Cancer Vaccines
Table 5. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2018-2023)
Table 9. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2024-2033)
Table 11. Oncolytic Virus Cancer Immunotherapy Market Trends
Table 12. Oncolytic Virus Cancer Immunotherapy Market Drivers
Table 13. Oncolytic Virus Cancer Immunotherapy Market Challenges
Table 14. Oncolytic Virus Cancer Immunotherapy Market Restraints
Table 15. Global Oncolytic Virus Cancer Immunotherapy Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players (2018-2023)
Table 17. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2022)
Table 18. Ranking of Global Top Oncolytic Virus Cancer Immunotherapy Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
Table 22. Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2018-2023)
Table 26. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2024-2033)
Table 28. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2018-2023)
Table 30. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2024-2033)
Table 32. North America Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 33. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2033) & (US$ Million)
Table 35. Europe Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2033) & (US$ Million)
Table 38. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 39. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2024-2033) & (US$ Million)
Table 41. Latin America Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 42. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2033) & (US$ Million)
Table 44. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 45. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2033) & (US$ Million)
Table 47. AstraZeneca Company Detail
Table 48. AstraZeneca Business Overview
Table 49. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product
Table 50. AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 51. AstraZeneca Recent Development
Table 52. Amgen Company Detail
Table 53. Amgen Business Overview
Table 54. Amgen Oncolytic Virus Cancer Immunotherapy Product
Table 55. Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 56. Amgen Recent Development
Table 57. F Hoffman-La Roche Company Detail
Table 58. F Hoffman-La Roche Business Overview
Table 59. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product
Table 60. F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 61. F Hoffman-La Roche Recent Development
Table 62. Bristol-Myers Squibb Company Detail
Table 63. Bristol-Myers Squibb Business Overview
Table 64. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product
Table 65. Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 66. Bristol-Myers Squibb Recent Development
Table 67. Novartis AG Company Detail
Table 68. Novartis AG Business Overview
Table 69. Novartis AG Oncolytic Virus Cancer Immunotherapy Product
Table 70. Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 71. Novartis AG Recent Development
Table 72. Merck & Co., Inc. Company Detail
Table 73. Merck & Co., Inc. Business Overview
Table 74. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product
Table 75. Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 76. Merck & Co., Inc. Recent Development
Table 77. Pfizer Company Detail
Table 78. Pfizer Business Overview
Table 79. Pfizer Oncolytic Virus Cancer Immunotherapy Product
Table 80. Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Biovex Company Detail
Table 83. Biovex Business Overview
Table 84. Biovex Oncolytic Virus Cancer Immunotherapy Product
Table 85. Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 86. Biovex Recent Development
Table 87. Cell Genesys Company Detail
Table 88. Cell Genesys Business Overview
Table 89. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product
Table 90. Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 91. Cell Genesys Recent Development
Table 92. Crusade Laboratories Company Detail
Table 93. Crusade Laboratories Business Overview
Table 94. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product
Table 95. Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 96. Crusade Laboratories Recent Development
Table 97. Genelux Corporation Company Detail
Table 98. Genelux Corporation Business Overview
Table 99. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product
Table 100. Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 101. Genelux Corporation Recent Development
Table 102. Lokon Pharma Company Detail
Table 103. Lokon Pharma Business Overview
Table 104. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product
Table 105. Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 106. Lokon Pharma Recent Development
Table 107. MultiVir Company Detail
Table 108. MultiVir Business Overview
Table 109. MultiVir Oncolytic Virus Cancer Immunotherapy Product
Table 110. MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 111. MultiVir Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type: 2022 VS 2033
Figure 3. Monoclonal Antibodies Features
Figure 4. Checkpoint Inhibitors Features
Figure 5. Oncoloytic Viral Therapies and Cancer Vaccines Features
Figure 6. Global Oncolytic Virus Cancer Immunotherapy Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 7. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2022 VS 2033
Figure 8. Lung Cancer Case Studies
Figure 9. Breast Cancer Case Studies
Figure 10. Colorectal Cancer Case Studies
Figure 11. Melanoma Case Studies
Figure 12. Prostate Cancer Case Studies
Figure 13. Head and neck Cancer Case Studies
Figure 14. Ovarian Cancer Case Studies
Figure 15. Pancreatic Cancer Case Studies
Figure 16. Others Case Studies
Figure 17. Oncolytic Virus Cancer Immunotherapy Report Years Considered
Figure 18. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 20. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region: 2022 VS 2033
Figure 21. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players in 2022
Figure 22. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2022)
Figure 23. The Top 10 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2022
Figure 24. North America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. North America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2033)
Figure 26. United States Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Canada Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Europe Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2033)
Figure 30. Germany Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. France Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. U.K. Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Italy Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Russia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Region (2018-2033)
Figure 38. China Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Japan Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. South Korea Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. India Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Australia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Latin America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2033)
Figure 46. Mexico Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Brazil Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2033)
Figure 50. Turkey Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 51. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 52. AstraZeneca Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 53. Amgen Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 54. F Hoffman-La Roche Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 55. Bristol-Myers Squibb Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 56. Novartis AG Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 57. Merck & Co., Inc. Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 58. Pfizer Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 59. Biovex Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 60. Cell Genesys Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 61. Crusade Laboratories Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 62. Genelux Corporation Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 63. Lokon Pharma Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 64. MultiVir Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed